# Peyton Greenside

> Peyton Greenside is the CEO and co-founder of BigHat Biosciences, a San Mateo-based biotech company she co-founded in 2019 with Mark DePristo. A pioneer of deep learning applied to life science, Greenside combined a PhD in Biomedical Informatics from Stanford, an MPhil from Cambridge, and a BA in Applied Math from Harvard into a singular mission: use machine learning and synthetic biology to design safer, more effective antibody therapeutics faster than anyone thought possible. BigHat's Milliner platform generates thousands of unique antibody designs per week, and the company has raised $174M in total funding with pharma partnerships spanning Amgen, Merck, AbbVie, Johnson & Johnson, and Eli Lilly.

- **Role:** CEO & Co-Founder at BigHat Biosciences
- **Organizations:** BigHat Biosciences, Broad Institute, Valis, Schmidt Science Fellows
- **Nationality:** American
- **Education:** PhD in Biomedical Informatics (Accel Innovation Scholar), Stanford University, MPhil in Computational Biology (Herchel Smith Scholar), University of Cambridge, BA in Applied Mathematics, Harvard University
- **Known for:** Co-founded BigHat Biosciences in 2019, raising $174.56M in total funding, Inaugural Schmidt Science Fellow (2018 cohort), Named one of Silicon Valley Business Journal's 2021 Women of Influence

## Career timeline

- **2009-2012** — BA in Applied Mathematics, Harvard University
- **2012-2013** — MPhil in Computational Biology, University of Cambridge (Herchel Smith Scholar)
- **2013-2018** — PhD in Biomedical Informatics, Stanford University (Accel Innovation Scholar)
- **2018** — Inaugural Schmidt Science Fellow - worked with Prof. Emma Brunskill at Stanford on ML for experimental design
- **2018-2019** — Computational Biologist at the Broad Institute
- **2019** — Scientific founder of Valis
- **2019** — Co-founded BigHat Biosciences with Mark DePristo
- **2019-2025** — Co-Founder & Chief Scientific Officer, BigHat Biosciences
- **2021** — Named one of Silicon Valley Business Journal's 2021 Women of Influence
- **2022** — BigHat raises $75M Series B led by Section 32, with Amgen Ventures and Bristol Myers Squibb participation
- **2024** — BigHat named to Fierce Biotech 15; Peyton climbs Mt. Kilimanjaro for Sickle Forward campaign (Sept 8-17)
- **2025** — Transitions from CSO to CEO of BigHat Biosciences as company targets first clinical trials in 2026
- **2025** — Appeared on The Long Run podcast (Episode 178) discussing ML-guided biologics discovery (May 2025)

## Achievements

- Co-founded BigHat Biosciences in 2019, raising $174.56M in total funding
- Inaugural Schmidt Science Fellow (2018 cohort)
- Named one of Silicon Valley Business Journal's 2021 Women of Influence
- Biocom Catalyst Award winner (under 40 in life sciences)
- Built the Milliner platform - claimed fastest, highest-scale antibody design system in the world, generating thousands of unique designs per week
- Secured pharmaceutical partnerships with Amgen, Merck, AbbVie, Johnson & Johnson, and Eli Lilly
- BigHat named to Fierce Biotech 15 (2024)
- Led BigHat to two pipeline programs targeting IND filings in 2026 (next-gen ADC for GI cancers; avidity-driven TCE for solid tumors)
- Raised $75M Series B (July 2022) with participation from Amgen Ventures and Bristol Myers Squibb
- Climbed Mt. Kilimanjaro for the Timmerman Traverse for Sickle Forward, raising funds for sickle cell disease diagnosis and treatment in sub-Saharan Africa

## Latest updates

- **2025-05** — Appeared on The Long Run podcast (Episode 178) with Luke Timmerman discussing ML-guided biologics discovery
- **2025-02** — Assumed CEO role at BigHat Biosciences, with co-founder Mark DePristo moving to advisory role
- **2024-10** — BigHat partnered with Lonza's Synaffix to develop ML-designed ADC pipeline programs
- **2024-09** — Climbed Mt. Kilimanjaro for the Timmerman Traverse for Sickle Forward fundraiser
- **2024-07** — BigHat named to Fierce Biotech 15 (2024 cohort)
- **2024-04** — BigHat partners with Lilly to advance ML-enabled biologics discovery through Lilly TuneLab
- **2023-12** — BigHat and AbbVie announce research collaboration for next-gen therapeutic antibodies

## Links

- Website: https://bighatbio.com
- LinkedIn: https://www.linkedin.com/in/peyton-greenside-298a5881

---

Profile page: https://yespress.io/peyton-greenside
Published by YesPress — https://yespress.io
Last updated: 2026-05-11